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Purpose: To estimate the joint effects of single nucleotide polymorphysms (SNPs) in the genes complement factor H
(CFH), HtrA serine peptidase 1 (HTRA1), and age-related maculopathy susceptibility 2 (LOC387715/ARMS2) in a
Caucasian age related macular degeneration (AMD) case-control cohort.
Methods: We genotyped three SNPs, rs1061170 (exon 9, CFH), rs11200638 (HTRA1 promoter, −512 bp), and rs10490924
(6.6 kb upstream of HTRA1 in LOC387715/ARMS2) in 333 cases with advanced AMD (choroidal neovascularization
[CNV] and geographic atrophy) and 171 age-matched examined controls. Association tests were performed for individual
SNPs and jointly with the CFH SNP Y402H. Analyses for interaction were also performed.
Results: The linkage disequilibrium measure for two SNPs on 10q26, rs10490924 and rs11200638, is D'=0.8 and all four
possible haplotypes of the two SNPs were detected in the samples. The allelic association test for rs11200638 on the
promoter of HTRA1 yielded p-values less than 10−10 for geographic atrophy, less than 10−16 for neovascularization, and
less than 10−19 for the pooled phenotypes (with an odds ration [OR] of 3.973; 95% confidence interval [CI] 2.928, 5.390).
Disease risk is conferred in a dosage-dependent fashion. Similar figures were observed for the LOC387715/ARMS2 SNP.
No interaction was detected between either between the 10q26 SNPs or the CFH SNP.
Conclusions: This is the first analysis to show that the two 10q26 SNPs are not in complete linkage disequilibrium. Our
studies however show that both the HTRA1 and LOC387715/ARMS2 SNP appear to contribute equally to disease risk
(both geographic atrophy and choroidal neovascularization) with no evidence of interaction with CFH.
Several  genes  have  now  been  associated  with  the
development of age-related macular degeneration (AMD).
The most consistently identified genetic variants lie within the
regulators  of  complement  activation  (RCA)  locus  on
chromosome 1, principally the gene complement factor H
(CFH)  [1-3],  and  the  10q26  chromosomal  region  [4-6].
Association analyses of this latter locus initially implicated
the  single  nucleotide  polymorphism  (SNP)  rs10490924,
located in the coding sequence of a gene now known as age-
related maculopathy susceptibility 2 (ARMS2) [4-6], to be the
variant  most  likely  associated  with  AMD.  Subsequent
rigorous sequencing of the region revealed a polymorphism,
rs11200638, in the promoter of the adjacent gene, HtrA serine
peptidase 1 (HTRA1), some 7 kb downstream of LOC387715/
ARMS2, to be also associated with advanced AMD [7,8]. To
date,  this  finding  has  been  corroborated  in  two  other
Caucasian [9,10] one central European [11], and one Japanese
[12] populations.
Intriguingly,  both  rs10490924  and  rs11200638  are  in
almost  complete  linkage  disequilibrium  in  all  cohorts
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examined thus far (D' >0.98) [7,12,13], limiting the ability of
genetic association analyses to resolve the functional variant.
Initial molecular biologic analyses suggest that the promoter
SNP  in  HTRA1,  a  gene  that  encodes  a  heat  shock  serine
protease found in retinal tissues, produces a change in the
expression  level  of  the  gene  [7,8].  Interestingly,  HTRA1
expression has been reported to increase with age [14].
Most recently, LOC387715/ARMS2 has been suggested
to encode a mitochondrial-associated protein that is also found
in  the  retina.  The  polymorphism  which  results  in  the
substitution of serine-for-alanine at position 69 may result in
misfolding of the protein [15].
In this article, we present further analyses of the 10q26
polymorphisms in a Caucasian population from the USA with
advanced  AMD  (both  geographic  atrophy  and  choroidal
neovascularization) and assess joint effects of the HTRA1
rs11200638 SNP, the LOC387715/ARMS2 SNP rs10490924
(A69S), and the CFH SNP rs1061170 (Y402H).
METHODS
Phenotyping: Haplotype analyses of these two closely located
SNPs were therefore employed using SNPHAP and PHASE
programs  (Table  7).  Under  the  regression  framework,  no
interaction was detected between the 10q26 haplotypes and
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1395the CFH SNP (Table 8). After dropping the interaction term
the effect of one controlled for the other can be estimated and
tested for significance based on the likelihood ratio test (Table
9). Estimated haplotype frequencies, diplotype counts, odds
ratio,  and  p-values  for  testing  independ  for  all  observed
diplotypes are provided in Table 10.
Sporadic advanced cases (average age 79 years of age,
range 60 to 100 years of age) and controls (average age 74,
range 63 to 92 years of age, Table 1) of Northern European
Caucasian descent were ascertained from the clinical practices
of P.F. and M.K. Diagnosis of AMD in was based upon the
presence  of  geographic  atrophy  or  choroidal
neovascularization  (CNV;  equivalent  to  Age-Related  Eye
Disease Study [AREDS] category 4) [16]. Control subjects
were at least 60 years of age, with no signs of AMD (defined
as no drusen larger than 63 μm in diameter; equivalent to
AREDS category 1).
One hundred and eight patients with geographic atrophy
(GA) together with 205 patients with CNV, 20 with both GA
and  CNV,  and  171  age-matched  examined  controls  were
ascertained.  Informed  consent  was  obtained  from  all
participants, and the procedures used conformed to the tenets
of the Declaration of Helsinki.
Genotyping:  Genotyping  of  rs1061170,  rs10490924,  and
rs11200638  was  performed  as  described  previously  [17].
Specifically, PCR was performed using primers designed to
amplify  the  genomic  region  containing  each  SNP
(rs10490924 forward: 5′-GGT GGT TCC TGT GTC CTT
CA-3′, reverse: 5′-GGG GTA AGG CCT GAT CAT CT-3′;
rs11200638 forward: 5′-CGG ATG CAC CAA AGA TTC
TABLE 1. SUMMARY OF AGE DISTRIBUTIONS FOR THE FOUR PHENOTYPIC GROUPS
Phenotype Sample size Min 1st quantile Mean Max
Control 171 58 68 73 92
Dry 108 48 75 79 95
Dry+Wet 20 69 74 79 91
Wet 205 40 74 78 100
Counts, Hardy-Weinberg equilibrium tests, allele frequencies, genotypic association tests for three risk SNPs in each and
combined cohorts.
TABLE 2. GENOTYPING INFORMATION AND FISHER’S EXACT TESTS FOR ASSOCIATION BETWEEN SNPS AND DISEASE STATUS
SNP rs11200638
(HTRA1 promoter SNP)
rs10490924
(LOC387715/ARMS2)
rs1061170
(CFH)
HWE χ2 5.37 0.702 0.116
Genotypic /Allelic test
GA 2.05e-8/ 6.94e-11 2.36e-9 / 9.83e-12 1.14e-6 / 4.80e-7
GA+CNV 7.86e-7 / 1.33e-8 3.97e-7 / 1.92e-8 3.98e-3 / 1.31e-3
CNV 9.82e-15 / 1.67e-17 6.39e-16 / 2.42e-17 9.60e-6 / 1.96e-6
Pooled cases 2.70e-17 / 7.55e-21 3.12e-17 / 1.10e-19 4.78e-8 / 1.52e-8
Odd Ratio (95% CI) 3.973 (2.928, 5.390) 4.671 (3.245, 6.722) 2.399 (1.768, 3.256)
Genotyping data confirming Hardy-Weinberg equilibrium for all SNPs analyzed. Fisher’s exact tests shows strong association
between  SNPs  and  advanced  AMD  disease  status.  Abbreviations:  HWE=Hardy–Weinberg  Equilibrium.  Fisher’s  exact
genotypic / allelic  association  test  for  various  disease  status:  p-value.  GA=geographic  atrophy,  CNV=choroidal
neovascularization, GA+CNV refers to those individuals with GA and CNV in one or both eyes.
TABLE 3. HAPLOTYPE FREQUENCIES WITH ESTIMATED STANDARD DEVIATIONS IN PARENTHESES
Haplotype
rs10490924 +
rs11200638) Pooled sample Case Control
GG 0.412 (0.006) 0.277 (0.006) 0.679 (0.014)
GA 0.190 (0.005) 0.229 (0.006) 0.114 (0.006)
TG 0.124 (0.007) 0.143 (0.006) 0.087 (0.014)
TA 0.273 (0.005) 0.351 (0.007) 0.119 (0.005)
Haplotype frequencies for the LOC387715 and HTRA1 SNPs (with estimated standard deviations in parentheses) showing the
presence of all four potential haplotypes in the cohort. P-value for independence between haplotypes and disease: 1.1e-22.
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(TCC-3′, reverse: 5′-TTC GCG TCC TTC AAA CTA ATG
G-3′). Following amplification, genotype determination was
performed  on  the  PCR  products  using  either  temperature
gradient  capillary  electrophoresis  (TGCE;  REVEAL;
SpectruMedix,  State  College,  PA)  or  through  direct
sequencing  using  CEQ2000XL  DNA  analysis  system
(Beckman Coulter, Fullerton, CA).
Statistical analyses: Hardy–Weinberg Equilibrium (HWE) χ2
values in the entire sample and controls alone were calculated
to identify possible genotyping errors. No extreme deviations
(i.e., χ2 > 50) were observed (Table 2). Linkage disequilibrium
(LD) was measured by the D' value. For each SNP, Pearson’s
χ2  tests  with  one  degree  of  freedom  for  association  were
performed. Odds ratios (OR) and their respective confidence
intervals were calculated, [18]. Both SNPHAP and PHASE
were  used  to  estimate  the  haplotype  frequencies  and  to
reconstruct the diplotype (haplotype pair) for each sample.
Consistent results obtained by using both algorithms were
taken for further regression analyses.
Joint ORs for two SNPs (rs11200638 and complement
factor  H  (CFH)  Y402H,  previously  genotyped)  were
calculated using standard methods [19]. Marginal ORs and
their confidence intervals for the two SNPs were calculated
using  logistic  regression  with  SNPs  CFH  Y402H  and
rs11200638  as  independent  variables  [19].  The  standard
logistic regression models for marginal and joint effect (effect
TABLE 4. JOINT AND MARGINAL ODDS RATIOS (POOLED CASES) FOR RS11200638 AND RS1061170
rs11200638 rs1061170
rs11200638
risk (adjusted for
rs1061170)
TT TC CC
GG 1 3.53 3.92 1
GA 4.45 11.69 25.98 4.30 (95% CI: 2.50, 7.39)
AA 6.33 15.55 192.71 8.13 (95% CI: 3.70, 17.87)
rs1061170
risk (adjusted for rs11200638)
1 3.17 (95%
                  CI: 1.77, 5.66)
     5.74 (95%
 CI: 2.75,11.98)
Marginal odds ratios are calculated based on a logistic regression model by assuming an additive effect of two SNPs after a
logit transformation on odds ratio
TABLE 5. JOINT AND MARGINAL ODDS RATIOS (POOLED CASES) FOR RS10490924 AND RS1061170
rs10490924 rs1061170                                                                                   rs10490924
risk (adjusted for
rs1061170)
TT TC CC
GG 1 3.59 4.38 1
GT 5.72 13.66 36.52 5.24 (95% CI: 3.08,
8.91)
TT 7.63 38.77 227.57 15.30 (95% CI:
5.75,40.73)
rs1061170
risk (adjusted for
rs10490924)
1 3.32 (95% CI: 1.87, 5.91) 6.12 (95% CI: 2.92, 12.85)
Marginal odds ratios are calculated based on a logistic regression model by assuming an additive effect of two SNPs after a
logit transformation on odds ratio.
TABLE 6. JOINT GENOTYPE COUNTS IN CASES/CONTROLS FOR RS10490924 AND RS1061170
rs11200638
rs10490924 77/74 39453 0/0
0/5 27/117 39549
0/2 0/5 24959
Joint genotype counts of controls/cases, sample size too small to fit regression model with interaction terms.
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logit(p)=β0 + β1X1 and logit(p)=β0 + β1X1 + β2X2, respectively.
For highly correlated SNPs (rs10490924 and rs11200638), an
interaction term was incorporated in the model: logit(p)=β0 +
β1X1 + β2X2 + β3X1×X2.
To assess the statistical significance of the effect, the
likelihood ratio test is performed. To control for confounding,
the  Mantel-Hanzel  (M-H)  test  for  association  with  two
variables  was  used  [19].  Four  genotypic  models  were
considered (Full, Recessive, Multiplicative, and Dominant)
and  the  conventional  Aikake  information  criterion  (AIC)
[20] was used to assess the fit of each model.
RESULTS
In  our  US  Caucasian  case-control  cohort,  the  HTRA1
rs11200638 SNP showed strong disease association with both
advanced  forms  of  AMD,  p<10−10  (geographic  atrophy),
p<10−16  (neovascularization),  and  p<10−20  for  pooled
phenotypes.  The  LOC387715/ARMS2  rs10490924  SNP
showed similar levels of association. Strong association is also
confirmed  between  disease  status  and  the  CFH  SNP
rs1061170 (Table 2).
The two 10q26 SNPs, rs11200638 and rs10490924, were
also in strong linkage disequilibrium (D'=0.80), though not in
complete LD as all possible diplotypes were found in the
population. Table 3 shows how the four potential haplotypes
produced by the two SNPs were distributed; AMD cases were
approximately three times more likely to have the high risk
haplotype rs10490924 ‘T’ + rs11200638 ‘A’ than controls.
Table 4 shows joint and marginal odds ratios for the
HTRA1 and CFH SNPs. Odds ratios of having the disease rise
to almost 200 in individuals who are homozygous for the risk
alleles in both genes. Similar odds ratios are observed for the
LOC387715/ARMS2 and CFH SNP (Table 5). When joint
odds ratios were computed for the two highly correlated SNPs
on  10q26  and  the  interaction  terms  considered  in  the
regression  model,  the  resulting  confidence  interval
encompasses 0 and ∞ due to insufficient sample size in each
cell (Table 6).
DISCUSSION
Our data confirm the association between advanced AMD
(both geographic atrophy and CNV) and the 10q26 SNPs
rs11200638  (HTRA1  promoter)  and  rs10490924
(LOC387715/ARMS2 A69S), independent of the CFH Y402H
polymorphism. In all previous papers which examined linkage
disequilibrium in the 10q26 region, these two SNPs have been
reported to be in almost complete linkage disequilibrium [7,
13]. This was not the case in our population where the D'
between the SNPs was 0.80. This is a critical finding as it does
indicate that other studies using larger populations may be
able to determine which of the two 10q26 SNPs may be
contributing most to disease status. The number of individuals
in our study was too small to permit this. Odds ratios of having
TABLE 7. TESTS FOR MODEL FIT OF THE EFFECTS IN RS11200638 AND RS1061170
Model for 
rs11200638
x rs1061170
PAR % (95% CI)                              M-H test: p-value                                  LRT:
p-value
AIC
value
rs11200638              rs1061170               rs11200638                rs1061170
Full 58.0
(46.4, 67.0)
62.8
(45.5, 74.4)
4.24e-11 2.07e-6 1.20e-2 398.3
Rec x Rec 21.6
(13.9, 28.7)
20.1
(10.2, 28.9)
1.08e-4 2.20e-3 2.12e-2 439.5
Rec x Mul 21.7
(14.4, 28.7)
75.7
(63.3, 83.8)
1.05e-4 2.11e-6 1.62e-1 425.6
Rec x Dom 22.3
(14.4, 29.4)
60.4
(43.1, 73.6)
3.73e-5 3.38e-6 4.28e-1 428.6
Mul x Rec 67.2
(59.1, 74.0)
19.8
(8.8, 28.5)
6.11e-11 3.06e-3 2.15e-2 411.7
Mul x Mul 67.4
(60.1, 73.9)
76.1 (64.9,84.1) 4.24e-11 2.07e-6 1.45e-1 397.5
Mul x Dom 67.7
(59.8, 74.2)
62.0
(45.0, 74.9)
1.03e-11 2.83e-6 7.45e-1 399.3
Dom x Rec 56.9
(45.2, 66.2)
20.7
(10.3, 29.2)
3.63e-11 1.71e-3 4.77e-2 412.5
Dom x Mul 57.5
(47.1, 66.0)
76.7
(66.1, 84.3)
2.51e-11 1.06e-6 2.47e-1 397.8
Dom x Doc 58.2
(47.4, 67.3)
62.9
(45.7, 74.9)
6.88e-12 1.80e-6 9.51e-1 400.6
Models for  rs11200638   × rs1061170. Note: According to AIC value, Mul x Mul model fits the data best. Similar results for
rs10490924 × rs1061170 .
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1398advanced AMD, when adjusted for the CFH SNP, were not
significantly different for either of the 10q26 SNPs genotyped
in our cohort. Each of the two SNPs also confers similar odd
ratios when combined with the CFH SNP. Neither SNP was
more clearly associated with disease status nor with advanced
AMD phenotype though arguably if our cohort is enlarged
substantially it might be possible to distinguish which SNP
contribute the most risk.
Previous  studies  [21]  have  not  identified  gene-locus
interaction  between  CFH  and  the  region  on  chromosome
10q26. Our analyses are in agreement with this. Thus it seems
likely that CFH and 10q26 contribute independently to AMD
development, at least at the genomic level.
There remains an enormous amount to be learned about
the  genetic  etiology  of  AMD.  Nonetheless,  there  is  little
question that either HTRA1 and/or LOC387715/ARMS2 or a
10q26 haplotype that expands more than two SNPs play a
crucial role in determining the advanced AMD phenotypes.
Functional  consequences  from  the  polymorphisms  of
LOC387715/ARMS2 or HTRA1, or even CFH, have yet to be
determined. Our current data indicate that in a Caucasian
population  from  the  USA,  the  HTRA1  promoter  SNP  is
strongly associated with advanced AMD but appears to exert
its effect independently of CFH.
TABLE 8. JOINT ANALYSES OF THE CFH SNP AND 10Q26 HAPLOTYPES
rs10490924
+ rs11200638
rs10490924
+ rs11200638 risk
(adjusted for
rs1061170)
TT TC CC
GG/GG 1 2.09 4.48 1
Non GG/GG 5.44 14.4 26.86 6.49 (95% CI: 4.01, 10.50)
rs1061170
risk (adjusted for rs10490924 +
rs11200638)
1 2.34 (95%
                            CI: 1.34, 4.08)
4.90 (95%
 CI: 2.40,10.00)
The haplotype information for 10q26 gene is estimated using software PHASE. By treating the haplotype GG (formed by high
risk alleles G and G at rs10490924 and rs11200638) as a new “allele”, we studied the joint and main effects of CFH SNP-10q26
haplotypes as in Table 3. Here a recessive mode of inheritance for 10q26 gene is assumed so that the gentotypes are classified
to GG/GG and non GG/GG.
TABLE 9. ESTIMATED FREQUENCIES AND THEIR STANDARD DEVIATIONS OF HAPLOTYPES FOR RS10490924 AND RS11200638
Haplotype (rs10490924
+rs11200638)
Pooled sample Case Control
GG 0.412 (0.006) 0.277 (0.006) 0.679 (0.014)
GA 0.190 (0.005) 0.229 (0.006) 0.114 (0.006)
TG 0.124 (0.007) 0.143 (0.006) 0.087 (0.014)
TA 0.273 (0.005) 0.351 (0.007) 0.119 (0.005)
Presented in parentheses are estimated standard deviations. All the results were obtained by software SNPHAP using joint
genotypes of SNPs rs10490924 and rs11200638.
TABLE 10. COUNTS, ODDS RATIO, AND P-VALUE FOR TESTING INDEPENDENCE FOR ALL OBSERVED DIPLOTYPES (RS10490924 X RS11200638)
GG/GG GG/GA GG/TG TG/TG GG/TA GA/TA TG/TA TA/TA
Case 134 1 0 0 11 33 5 0
Control 89 6 5 2 37 139 73 13
Odds ratio 1 --- --- --- 5.06 (95% CI:
2.45,10.45)
6.34 (95% CI:
3.99,10.09)
21.98(95% CI:                   ---
P-value --- 0.02 0.01 0.16 2.62e-6 1.51e-16 2.41e-18 1.16e-5
Odds ratios and their CIs are based on logistic regression models. Where counts are less than 6, ORs are ignored; p-values are
for Fisher’s exact tests. The phase-known diplotypes and estimated diplotypes were pooled, which were sufficient for haplotype
analyses. P-value for testing independence of disease and all diplotypes is 4.76e-24.
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